Episode
Managing CML: What HCPs Need to Know
- Podcast
- Treating Blood Cancers
- Published
- Nov 6, 2025
- Duration seconds
- 2239
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/treating-blood-cancers-14318/episodes/managing-cml-what-hcps-need-to-know/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/treating-blood-cancers-14318/managing-cml-what-hcps-need-to-know.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on October 23, 2025 Michael J. Mauro, MD Director, Chronic Myeloid Leukemia Program Professor of Medicine, Leukemia Service Memorial Sloan Kettering Cancer Center New York, NY Tune in for this expert-led discussion with Dr. Michael Mauro from Memorial Sloan Kettering Cancer Center on the evolving management of chronic myeloid leukemia (CML) in the era of tyrosine kinase inhibitors (TKIs) and newly approved FDA therapies. Dr. Mauro explores how TKIs have transformed prognosis, key factors guiding initial therapy selection, and best practices for managing treatment-related side effects. He also shares updates on TKI discontinuation criteria, long-term monitoring, and a forward look at ongoing trials and emerging therapeutic advances shaping the future of CML care. Gain actionable insights to enhance patient outcomes today!